Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open
Eli Lilly shares closed Thursday near $1,006 after new Phase 3 data showed its obesity drug retatrutide cut body weight by up to 28.7% in patients with knee osteoarthritis. The company announced a $6 billion plant in Alabama and reported Q3 revenue up 54% to $17.6 billion. Mounjaro will be covered by China’s national health insurance from January.